Association of chronic hypertension with birth of small-for-gestational-age neonate

A M Panaitescu1, A A Baschat2, R Akolekar1,3

  • 1Department of Fetal Medicine, King's College Hospital, London, UK.

Insights

Chronic hypertension (CH) significantly increases the risk of small-for-gestational-age (SGA) neonates, particularly when pre-eclampsia (PE) is absent. Mean arterial pressure in early pregnancy is a key factor in this association.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Perinatology

Background:

  • Chronic hypertension (CH) is a common complication of pregnancy.
  • The impact of CH, with or without superimposed pre-eclampsia (PE), on fetal growth requires further elucidation.
  • Understanding the mechanisms linking CH to adverse pregnancy outcomes is crucial for improved management.

Purpose of the Study:

  • To investigate the association between chronic hypertension (CH) and the incidence of small-for-gestational-age (SGA) neonates.
  • To determine if superimposed pre-eclampsia (PE) modifies this association.
  • To explore the role of mean arterial pressure (MAP) in mediating these effects.

Main Methods:

  • Prospective screening of 74,226 singleton pregnancies at 11-13 weeks' gestation.
  • Recording maternal characteristics, medical history, and mean arterial pressure (MAP).
  • Comparing birth-weight Z-scores and SGA incidence between women with and without CH, stratified by PE status; regression analysis used to assess MAP's impact.

Main Results:

  • In pregnancies without PE, CH doubled the incidence of SGA compared to normotensive pregnancies.
  • In pregnancies with PE, no significant difference in SGA incidence or birth-weight Z-score was observed between CH and non-CH groups.
  • Elevated MAP at 11-13 weeks' gestation was significantly associated with increased SGA and PE risk, more pronounced in women with CH.

Conclusions:

  • Chronic hypertension (CH) is linked to a higher risk of small-for-gestational-age (SGA) neonates and pre-eclampsia (PE).
  • This association is mediated by mean arterial pressure (MAP) measured in early pregnancy (11-13 weeks' gestation).
  • MAP measurement in early pregnancy may aid in identifying pregnancies at risk for SGA and PE in women with CH.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
679
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
3.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.2K